Bristol Myers Squibb (BMY) Non-Current Debt (2009 - 2026)
Bristol Myers Squibb (BMY) reported Non-Current Debt of $42.2 billion for Q1 2026, down 8.68% year-over-year from $46.2 billion in Q1 2025, and down 1.63% on a QoQ basis from $42.8 billion in Q4 2025.
Bristol Myers Squibb (BMY) has 18 years of Non-Current Debt data on file, last reported at $42.2 billion in Q1 2026.
- Quarterly Non-Current Debt fell 8.68% year-over-year to $42.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.2 billion (down 8.68% YoY) and the FY2025 annual result came in at $42.8 billion, down 9.98% from the prior year.
- Non-Current Debt retreated to $42.2 billion in Q1 2026 per BMY's latest filing, from $42.8 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $49.5 billion in Q1 2024 and bottomed at $32.1 billion in Q3 2023.
- The 5-year median for Non-Current Debt is $42.2 billion (2026), against an average of $41.2 billion.
- The widest annual swing landed in 2022, when Non-Current Debt retreated 15.85%; it then soared 51.46% in 2024.
- Tracing BMY's Non-Current Debt over 5 years: stood at $35.1 billion in 2022, then grew by 4.56% to $36.7 billion in 2023, then advanced by 29.87% to $47.6 billion in 2024, then retreated by 9.98% to $42.8 billion in 2025, then dropped by 1.63% to $42.2 billion in 2026.
- Per Business Quant, the three latest BMY Non-Current Debt figures stand at $42.2 billion (Q1 2026), $42.8 billion (Q4 2025), and $44.5 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 39.37 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 37.53 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 64.53 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 46.67 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 51.89 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 20.86 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 60.57 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 42.15 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 19.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.15 Bn |
| Mar 31, 2026 | 42.15 Bn |
| Dec 31, 2025 | 42.85 Bn |
| Dec 31, 2025 | 42.85 Bn |
| Sep 30, 2025 | 44.47 Bn |
| Sep 30, 2025 | 44.47 Bn |
| Jun 30, 2025 | 44.47 Bn |
| Jun 30, 2025 | 44.47 Bn |
| Mar 31, 2025 | 46.16 Bn |
| Mar 31, 2025 | 46.16 Bn |
| Dec 31, 2024 | 47.60 Bn |
| Dec 31, 2024 | 47.60 Bn |
| Sep 30, 2024 | 48.67 Bn |
| Sep 30, 2024 | 48.67 Bn |
| Jun 30, 2024 | 48.86 Bn |
| Jun 30, 2024 | 48.86 Bn |
| Mar 31, 2024 | 49.49 Bn |
| Mar 31, 2024 | 49.49 Bn |
| Dec 31, 2023 | 36.65 Bn |
| Dec 31, 2023 | 36.65 Bn |
| Sep 30, 2023 | 32.14 Bn |
| Sep 30, 2023 | 32.14 Bn |
| Jun 30, 2023 | 34.66 Bn |
| Jun 30, 2023 | 34.66 Bn |
| Mar 31, 2023 | 35.08 Bn |
| Mar 31, 2023 | 35.08 Bn |
| Dec 31, 2022 | 35.06 Bn |
| Dec 31, 2022 | 35.06 Bn |
| Sep 30, 2022 | 36.97 Bn |
| Sep 30, 2022 | 36.97 Bn |
| Jun 30, 2022 | 37.11 Bn |
| Jun 30, 2022 | 37.11 Bn |
| Mar 31, 2022 | 37.45 Bn |
| Mar 31, 2022 | 37.45 Bn |
| Dec 31, 2021 | 39.61 Bn |
| Dec 31, 2021 | 39.61 Bn |
| Sep 30, 2021 | 39.68 Bn |
| Sep 30, 2021 | 39.68 Bn |
| Jun 30, 2021 | 42.50 Bn |
| Jun 30, 2021 | 42.50 Bn |
| Mar 31, 2021 | 44.51 Bn |
| Mar 31, 2021 | 44.51 Bn |
| Dec 31, 2020 | 48.34 Bn |
| Dec 31, 2020 | 48.34 Bn |
| Sep 30, 2020 | 41.36 Bn |
| Sep 30, 2020 | 41.36 Bn |
| Jun 30, 2020 | 41.85 Bn |
| Jun 30, 2020 | 41.85 Bn |
| Mar 31, 2020 | 42.84 Bn |
| Mar 31, 2020 | 42.84 Bn |
| Dec 31, 2019 | 43.39 Bn |
| Dec 31, 2019 | 43.39 Bn |
| Sep 30, 2019 | 24.39 Bn |
| Sep 30, 2019 | 24.39 Bn |
| Jun 30, 2019 | 24.43 Bn |
| Jun 30, 2019 | 24.43 Bn |
| Mar 31, 2019 | 5.64 Bn |
| Mar 31, 2019 | 5.64 Bn |
| Dec 31, 2018 | 5.65 Bn |
| Dec 31, 2018 | 5.65 Bn |
| Sep 30, 2018 | 5.69 Bn |
| Sep 30, 2018 | 5.69 Bn |
| Jun 30, 2018 | 5.67 Bn |
| Jun 30, 2018 | 5.67 Bn |
| Mar 31, 2018 | 5.78 Bn |
| Mar 31, 2018 | 5.78 Bn |
| Dec 31, 2017 | 6.98 Bn |
| Dec 31, 2017 | 6.98 Bn |
| Sep 30, 2017 | 6.98 Bn |
| Sep 30, 2017 | 6.98 Bn |
| Jun 30, 2017 | 6.91 Bn |
| Jun 30, 2017 | 6.91 Bn |
| Mar 31, 2017 | 7.24 Bn |
| Mar 31, 2017 | 7.24 Bn |
| Dec 31, 2016 | 5.72 Bn |
| Dec 31, 2016 | 5.72 Bn |
| Sep 30, 2016 | 5.84 Bn |
| Sep 30, 2016 | 5.84 Bn |
| Jun 30, 2016 | 6.58 Bn |
| Jun 30, 2016 | 6.58 Bn |
| Mar 31, 2016 | 6.59 Bn |
| Mar 31, 2016 | 6.59 Bn |
| Dec 31, 2015 | 6.55 Bn |
| Dec 31, 2015 | 6.55 Bn |
| Sep 30, 2015 | 6.63 Bn |
| Sep 30, 2015 | 6.63 Bn |
| Jun 30, 2015 | 6.62 Bn |
| Jun 30, 2015 | 6.62 Bn |
| Mar 31, 2015 | 7.13 Bn |
| Mar 31, 2015 | 7.13 Bn |
| Dec 31, 2014 | 7.24 Bn |
| Dec 31, 2014 | 7.24 Bn |
| Sep 30, 2014 | 7.27 Bn |
| Sep 30, 2014 | 7.27 Bn |
| Jun 30, 2014 | 7.37 Bn |
| Jun 30, 2014 | 7.37 Bn |
| Mar 31, 2014 | 7.37 Bn |
| Mar 31, 2014 | 7.37 Bn |
| Dec 31, 2013 | 7.98 Bn |
| Dec 31, 2013 | 7.98 Bn |
| Sep 30, 2013 | 6.53 Bn |
| Sep 30, 2013 | 6.53 Bn |
| Jun 30, 2013 | 6.44 Bn |
| Jun 30, 2013 | 6.44 Bn |
| Mar 31, 2013 | 6.52 Bn |
| Mar 31, 2013 | 6.52 Bn |
| Dec 31, 2012 | 6.57 Bn |
| Dec 31, 2012 | 6.57 Bn |
| Sep 30, 2012 | 6.61 Bn |
| Sep 30, 2012 | 6.61 Bn |
| Jun 30, 2012 | 5.21 Bn |
| Jun 30, 2012 | 5.21 Bn |
| Mar 31, 2012 | 5.27 Bn |
| Mar 31, 2012 | 5.27 Bn |
| Dec 31, 2011 | 5.38 Bn |
| Dec 31, 2011 | 5.38 Bn |
| Sep 30, 2011 | 5.44 Bn |
| Sep 30, 2011 | 5.44 Bn |
| Jun 30, 2011 | 5.33 Bn |
| Jun 30, 2011 | 5.33 Bn |
| Mar 31, 2011 | 5.28 Bn |
| Mar 31, 2011 | 5.28 Bn |
| Dec 31, 2010 | 5.33 Bn |
| Dec 31, 2010 | 5.33 Bn |
| Dec 31, 2009 | 6.13 Bn |
| Dec 31, 2009 | 6.13 Bn |
| Sep 30, 2009 | 6.31 Bn |
| Sep 30, 2009 | 6.31 Bn |
| Jun 30, 2009 | 6.24 Bn |
| Jun 30, 2009 | 6.24 Bn |